JPRN-UMIN000008260招募中未知
Open-label, randomized parallel group trial on the efficacy and safety of intra-articular administration of bevacizumab for knee osteoarthritis. - Trial for the efficacy and safety of bevacizumab for knee osteoarthritis.
ational Hospital Organization Sagamihara Hospital0 个研究点目标入组 100 人开始时间: 2012年7月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 50years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients who do not have any significant physical, neurological, or mental problems. 2. Patients who do not have any significant disorders in motor systems. 3. Patients who are inadequate to enter the trial by physicians' judgments
研究者
相似试验
已完成
2 期
Therapeutic apps for control drinking or abstinence: A feasibility randomized controlled studyD000437alcohol dependenceJPRN-jRCTs062210005OUSO Kazuhiro40
进行中（未招募）
1 期
A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or non-alcoholic steatohepatitis (NASH) who have high blood pressure in the portal vein (main vessel going to the liver)EUCTR2021-005171-40-ATBoehringer-Ingelheim RCV GmbH & Co KG80
进行中（未招募）
1 期
A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or non-alcoholic steatohepatitis (NASH) who have high blood pressure in the portal vein (main vessel going to the liver)EUCTR2021-005171-40-DKBoehringer Ingelheim B. V.80
进行中（未招募）
1 期
A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or non-alcoholic steatohepatitis (NASH) who have high blood pressure in the portal vein (main vessel going to the liver)EUCTR2021-005171-40-DEBoehringer Ingelheim Pharma GmbH & Co. KG - Clinical Research Germany80
招募中
2 期
A study to test whether BI 685509 alone or in combination with empagliflozin helps people with liver cirrhosis caused by viral hepatitis or non-alcoholic steatohepatitis (NASH) who have high blood pressure in the portal vein (main vessel going to the liver)Patients with CSPH in compensated cirrhosis due to HBV, HCV, and NASH with or without T2DMJPRN-jRCT2031220376Kutsunai Mitsuru5